Proteoglycans as therapeutic agents (I);LES PROTEOGLYCANES I. MOLECULES AUX MULTIPLES FONCTIONS - FUTURES MOLECULES THERAPEUTIQUES?

Medecine/Sciences

Volumn 14, Issue 4, 1998, Pages 412-420

  Praillet, Christel ^d   Grimaud, Jean Alexis ^a,b   Lortat Jacob, Hugues ^c  

^a INSTITUT PASTEUR   (France)

^b CNRS   (France)

^c INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^d NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; CYTOKINE; GLYCOSAMINOGLYCAN; POLYSACCHARIDE; PROTEOGLYCAN;

CARTILAGE; CELL ADHESION; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURFACE; CELL SWELLING; CORNEA; COVALENT BOND; EXTRACELLULAR MATRIX; GLOMERULUS; HYDRATION; MOLECULAR INTERACTION; REVIEW; TISSUE PRESSURE;

GLOMERULUS;

EID: 0031894969     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/1056     Document Type: Review

References (38)

1. Wight TN, Heinegård DK, Hascall VC. Proteoglycans : structure and function. In : Hay ED, ed. Cell biology of extracellular matrix, 2nd ed. New York : Plenum Press, 1991 : 45-71.
2. Kjellén L, Lindahl U. Proteoglycans : structures and interactions. Annu Rev Biochem 1991 ; 60 : 443-75.
3. Silbert JE, Suguraman G. Intracellular membranes in the synthesis, transport, and metabolism of proteoglycans. Biochim Biophys Acta 1995 ; 1241 : 371-84.
4. Gallagher JT, Turnbull JE, Lyon M. Patterns of sulphation in heparan sulphate : polymorphism based on a common structural theme. Int J Biochem 1992 ; 24 : 553-60.
5. Salmivirta M, Lidholt K, Lindahl U. Heparan sulfate : a piece of information. FASEB J 1996 ; 10 : 1270-9.
6. Turnbull JE. Oligosaccharide mapping and sequence analysis of glycosaminoglycans. In : Graham JM, Higgins JA, eds. Biomembrane protocols I. Series : methods in molecular biology 19, Totowa : Humana Press, 1993: 253-67.
7. Ruoslahti E. Structure and biology of proteoglycans. Annu Rev Cell Biol 1988 ; 4 : 229-55.
8. Giry-Lozinguez C, Kleman J, Van der Rest M. Interactions moléculaires et modularité des protéines au sein des matrices extracellulaires. Med Sri 1994 ; 10 : 1234-43.
9. Jackson RL, Busch SJ, Cardin AD. Glyrosaminoglycans : molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991 ; 71 : 481-539.
10. Schönherr E, Hausser H, Beavan L, Kresse H. Decorin-type I collagen interaction : presence of separate core protein-binding domains. J Biol Chem 1995 ; 270 : 8877-83.
11. Nathan C, Sporn M. Cytokines in context. J Cell Biol 1991 ; 113 : 981-6.
12. Feige JJ, Baird A. La crinopexic : un modèle décrivant les mécanismes qui régissent la biodisponibilité des facteurs de croissance. Med Sri 1992 ; 8 : 805-10.
13. Blanquet P. Les signaux des FGF : un mécanisme qui commence à être déchiffré. Med Sci 1996 ; 12 : 303-12.
14. Praillet C, Lortat-Jacob H, Baltzer F, Grimaud JA. Distribution of hepatic glycosaminoglycans during acute schistosomiasis : modulation by IFNγ treatment. Cell Mol Biol 1996 ; 42 : 167-77.
15. 35S incorporation in heparan sulfate synthesized by human skin fibroblasts. FEBS Lett 1996 ; 387 : 109-12.
16. Praillet C, Lortat-Jacob H, Grimaud JA. Interferon γ differentially affects the synthesis of chondroitin/dermatan sulphate and heparan sulphate by human skin fibroblasts. Biochem J 1996 ; 318 : 863-70.
17. Lebaron RG, Höök A, Esko JD, Gay S, Höök M. Binding of heparan sulfate to type V collagen. A mechanism of cell-substrate adhesion. J Biol Chem 1989 ; 264 : 7950-6.
18. Venkataraman G, Sasisekharan V, Cooney CL, Langer R, Sasisekharan R. A stereochemical approach to pyranose ring flexibility : its implications for the conformation of dermatan sulfate. Proc Natl Acad Sci USA 1994 ; 91 : 6171-5.
19. Scott JE. Supramolecular organization of extracellular matrix glycosaminoglycans, in vitro and in tissues. FASEB J 1992 ; 6 : 2639-45.
20. Casu B, Petitou M, Provasoli M, Sinaÿ P. Conformational flexibility : a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci 1988 ; 13 : 221-5.
21. Pouzol P, Polack B. Les héparines de bas poids moléculaire. Quelle surveillance biologique? Techn Biol 1987 ; 2 : 46-50.
22. Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin like molecules bound to the endothclium. J Clin Invest 1984 ; 74 : 341-50.
23. Petitou M, Duchaussoy P, Lederman I, Choay J, Sinaÿ P. Binding of heparin to antithrombin III : a chemical proof of the critical role played by a 3-sulfated 2-amino-2-deoxy-D-glucose residue. Carbohydr Res 1988 ; 179 : 163-72.
24. Boneu B, Necciari J, Cariou R, Sié P, Gabaig AM, Kieffer G, Dickinson J, Lamond G, Moelker H, Mant T, Magnani H. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995 ; 74 : 1468-73.
25. Linhardt RJ, Hileman RE. Dermatan sulfate as a potential therapeutic agent. Gen Pharmacol 1995 ; 26 : 443-51.
26. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 1990 ; 346 : 281-4.
27. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992 ; 360 : 361-4.
28. Ruoslahti E, Yamaguchi Y, Hildebrand A, Border WA. Extracellular matrix/ Growth factor interactions. Cold Spring Harbor Symp Quant Biol 1992 ; LVII : 309-15.
29. Farrar MA, Schreiber RD, The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 1993 ; 11 : 517-611.
30. Lortat-Jacob H, Grimand JA. Interferongamma C-terminal function : new working hypothesis. Heparan sulfate and heparin, new targets for IFN-gamma, protect, relax the cytokine and regulate its activitv. Cell Mol Biol 1991 ; 37 : 253-60.
31. Lortat-Jacob H, Grimaud JA. La matrice extracellulaire : du tissu de soutien à la régulation des cytokines. Pathol Biol 1994 ; 42 : 612-20.
32. Lortat-Jacob H, Kleinman HK, Grimaud JA. Higli-affinity binding of interferon-γ to a basement membrane complex (matrigel). J Clin Invest 1991 ; 87 : 878-83.
33. Lortat-Jacob H, Grimand JA. Interferon-γ binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule. FEBS Lett 1991 ; 280 : 152-4.
34. Lortat-Jacob H, Baltzer F, Grimaud JA. Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its C-terminal sequence. J Biol Chem 1990 ; 271 : 16139-43.
35. Lortat-Jacob H, Baltzer F, Desmouliére A, Peyrol S. Grimaud JA. Lobular - but not periovular inhibition of collagen deposition in the liver of Schistosoma mansoni infected mice using IFNγ. J Hepatol 1997 ; 26 : 894-903.
36. Lortat-Jacob H, Brisson C, Guerret S, Morel G. Non-receptor-mediated tissular localizaition of human interferon-γ : role of heparan sulfate/heparin-like molecules. Cytokine 1996 ; 8 : 557-66.
37. Lortat-Jacob H, Turnbull JE, Grimaud JA. Molecular organization of the interteron γ - binding domain in heparan sulfate. Biochem J 1995 ; 310 : 497-505.
38. Lortat-Jacob H. Agent potentialisateur d'interféron-gamma. Brevet no 95 08723.